Evidence map›Paper›PMID 42865609›Full record

ArticleCase reports in endocrinology2026

Capivasertib-Associated Diabetic Ketoacidosis With Concurrent Myocardial Injury in a Patient With Pre-Existing Coronary Artery Disease.

Rabih A Noun, Ossama Sajeh Maadarani, Zouheir I Bitar

Abstract read
In one paragraph

Article in Case reports in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rabih A NounCardiology Specialist Internal Medicine Department Ahmadi Hospital Ahmadi Kuwait.ORCID https://orcid.org/0009-0006-0559-046X
Ossama Sajeh MaadaraniConsultant Cardiologist Internal Medicine Ahmadi Hospital Kuwait Oil Company Ahmadi Kuwait kockw.com.ORCID https://orcid.org/0000-0003-3658-4709
Zouheir I BitarConsultant in Critical Care Medicine Internal Medicine Department Ahmadi Hospital Ahmadi Kuwait.ORCID https://orcid.org/0000-0001-8426-8685

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Capivasertib is a serine/threonine kinase AKT (AKT1-3) inhibitor, disrupting phosphorylation of AKT substrates. When combined with fulvestrant, it is approved for hormone receptor-positive advanced breast cancer. Capivasertib therapy frequently causes hyperglycemia, including diabetic ketoacidosis (DKA). Ensure glycemic control before initiation and maintain ongoing blood glucose monitoring to reduce the risk of this potentially fatal complication. We present a case of metastatic breast cancer with initially controlled blood glucose who developed ketoacidosis and myocardial infarction during capivasertib therapy.

Indexed as

capivasertibischemic heart diseaseketoacidosis

Identifiers

PMID42865609
PMCPMC13655374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.